Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 SAX patients characteristics

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

  N = 148 %
Median age years (range) 62 (35–85)
Age
 < 75 126 85%
 ≥ 75 22 15%
Gender
 Male 75 50.7%
 Female 73 49.3%
ECOG PS
 0 82 55.4%
 1 61 41.3%
 2 5 3.3%
Nephrectomy
 Yes 134 90.5%
 No 14 9.5%
MOTZER score
 Poor 17 11.5%
 Intermediate 90 60.8%
 Favorable 41 27.7%
Heng score
 Poor 23 15.5%
 Intermediate 89 60.1%
 Favorable 36 24.3%
Principal sites of disease
 Lung 84 56.8%
 Lymph node 55 37.2%
 Bone 39 26.4%
 Liver 33 22.3%
 Adrenal glands 10 6.8%
 Brain 9 6.1%
 Local recurrence 8 5.4%
 Pancreas 7 4.7%
 Peritoneum 6 4.1%
 Contralateral kidney 5 3.4%
 Skin 3 2%
 Spleen 2 1.4%